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Summary
Objective: To determine the inﬂuence of osteoarthritic (OA) phenotype of subchondral osteoblasts on the phenotype of human chondrocytes.
Methods: Human chondrocytes were isolated from OA cartilage and cultured in alginate beads for 4 or 10 days in the absence or in the
presence of osteoblasts in monolayer. The osteoblasts were either isolated from non-sclerotic (N) or sclerotic (SC) zones of human
subchondral bone. Before co-culture, osteoblasts were incubated for 72 h with or without 1.7 ng/ml interleukin (IL)-1b, 100 ng/ml IL-6 with its
soluble receptor (50 ng/ml) or 10 ng/ml oncostatin M. SOX9, type I, II and X collagen (COL1, COL2, COL10), osteoblasts-stimulating factor
(OSF)-1, bone alkaline phosphatase (ALP), parathyroid hormone related peptide (PTHrP) and its receptor (PTH-R) messenger RNA (mRNA)
levels in chondrocytes were quantiﬁed by real-time polymerase chain reaction.
Results: In comparison with chondrocytes cultured alone in alginate beads, chondrocytes after 4 days in co-culture with N or SC osteoblasts
expressed signiﬁcantly less SOX9 and COL2 mRNA. The decrease of SOX9 and COL2 gene expression was signiﬁcantly more pronounced
in the presence of SC than in the presence of N osteoblasts (P! 0.001). OSF-1 mRNA level in chondrocyte was increased by both N and SC
osteoblasts, but to a larger extent by SC osteoblasts (P! 0.001). PTHrP expression in chondrocytes was 21-fold increased by N osteoblasts
but four-fold inhibited by SC osteoblasts. PTHrP secretion was also increased by N but reduced by SC osteoblasts. SC, but not N osteoblasts,
induced a signiﬁcant decrease of PTH-R gene expression in chondrocyte. In our experimental conditions, chondrocytes did not express COL1,
COL10 or ALP, even after 10 days of co-culture with osteoblasts.
Conclusions: In co-culture, SC subchondral osteoblasts decrease SOX9, COL2, PTHrP and PTH-R gene expression by chondrocytes but
increase that of OSF-1. These ﬁndings suggest that SC osteoblasts could initiate chondrocyte phenotype shift towards hypertrophic
differentiation and subsequently further matrix mineralization.
ª 2005 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Cartilage
Repair
SocietyIn mature adult articular cartilage, chondrocytes have
a stable phenotype with a low metabolic activity. Chon-
drocytic phenotype is characterized by a round shape, a low
rate of proliferation and the production of speciﬁc extracel-
lular matrix components, including type II collagen and
aggrecan. In OA, some phenotypic changes occur and
chondrocytes secrete proteins that are normally absent in
normal cartilage. They produce type I and III collagens,
which could be indicative for a dedifferentiation process of
these cells, but also alkaline phosphatase (ALP), osteocal-
cin (OC) and type X collagen (COL10), which indicate that
adult osteoarthritic chondrocyte may differentiate into
hypertrophic phenotype1,2. Until now, the factors inducing
*Address correspondence and reprint requests to: Dr Yves E.
Henrotin, Ph.D., Bone and Cartilage Metabolism Research Unit,
Institute of Pathology, University Hospital, CHU B23, Sart-Tilman,
B-4000 Lie`ge, Belgium. Tel: 32-4-366-24-67; Fax: 32-4-366-47-34;
E-mail: yhenrotin@ulg.ac.be
Received 13 October 2004; revision accepted 14 July 2005.9this phenotype shift in OA remain unknown. Herein, we
hypothesized that osteoarthritic (OA) subchondral osteo-
blasts could take part in this pathological mechanism. Since
the presence of connections (microcracks, vascular chan-
nels, neovascularization) between subchondral bone and
cartilage has been demonstrated, it is speculated that
mediators produced by subchondral osteoblasts could
modulate chondrocyte metabolism and induce chondrocyte
phenotype changes3,4. Further, it is now well established
that OA osteoblasts show an altered phenotype and secrete
more ALP, OC, interleukin (IL)-6, transforming growth factor
(TGF)-b1, insulin-like growth factor (IGF)-1, urokinase
plasminogen activator (uPA) and prostaglandin (PG)E2
than normal osteoblasts5e8. Therefore, we can hypothesize
that OA osteoblasts contribute to bone sclerosis and
degradation of overlying cartilage.
To verify this hypothesis, we have developed an original
co-culture model, in which subchondral osteoblasts in
monolayer are cultured together with OA chondrocytes in
alginate beads. In a previous work, we have demonstrated
that osteoblasts from sclerotic (SC) zones of subchondral OA88
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aggrecan synthesis and upregulated metalloproteases
expression by chondrocytes in this co-culture model9.
Herein, we propose to investigate the expression of genes
in chondrocytes that are commonly considered asmarkers of
normal cartilaginous phenotype [expression of SOX9 and
type II collagen (COL2) genes and no expression of type I
collagen (COL1)] or as indicators of the hypertrophic
differentiation [expression of ALP, COL10, parathyroid
hormone related peptide (PTHrP) and its receptor (PTH-R)
and osteoblasts-stimulating factor-1 (OSF-1) genes].
SOX9 is a high-mobility-group domain transcription
factor that is expressed in chondrocytes and other
tissues10. During chondrogenesis, SOX9 is expressed in
all chondrocyte progenitors and all differentiated chon-
drocytes, but its expression is completely turned off in
hypertrophic chondrocytes11. SOX9 expression parallels
to that of the gene coding for type II collagen (COL2A1),
a speciﬁc marker of chondrocyte differentiation12. In
mouse embryo, SOX9 knock-out embryonic stem cells
were excluded from chondrogenic mesenchymal conden-
sations and could not express chondrocyte-speciﬁc markers
such as COL2A1, COL11A2 and aggrecan10. Type I
collagen is normally absent of cartilage, and its deposition
occurs only in the late stage of OA when ﬁbrocartilage is
formed13,14. In vitro, type I collagen is expressed only
when chondrocytes become dedifferentiated, acquiring
a ﬁbroblast-like appearance and changing their pattern of
gene expression from one that expresses chondrocyte-
speciﬁc gene to one that resembles a ﬁbroblastic or
chondroprogenitor-like pattern15.
In endochondral growth, PTHrP is expressed principally
in the perichondrium and by resting and proliferative
chondrocytes, and the PTH/PTHrP receptor by proliferative
and prehypertrophic chondrocytes16,17. In early endochon-
dral mineralization, PTHrP acts by stimulating proliferation
of endochondral chondrocytes and inhibiting apoptosis,
partly via induction of bcl-2 (see Ref.18). Furthermore,
perichondrial PTHrP, acting on prehypertrophic endochon-
dral chondrocytes, acts as an inhibitor of hypertrophic
differentiation19. In other terms, PTHrP participates in
a negative biofeedback loop limiting entry into hypertrophy.
Although PTHrP is present in low quantities in normal adult
cartilage, it is found in high amount in OA human articular
cartilage. It was demonstrated that PTHrP is highly and
predominantly expressed by chondrocytes located in de-
generative lesions of osteoarthritic tissue20.
OSF-1, also called pleiotrophin, is a 15.3 kDa heparin-
binding peptide that is normally expressed in the epiphyseal
growth plate cartilage but not in articular cartilage. It is
re-expressed in OA chondrocytes21. OSF-1 exerts a chemo-
attractive effect on osteoblasts and stimulates the osteo-
blastic maturation22. In vitro, OSF-1 inhibits mature
chondrocyte proliferation and increases glycosaminoglycan
synthesis in bovine high-density chondrocytes culture23. OA
chondrocytes, but not normal cells, also expressed ALP,
which is considered as a marker of chondrocytes hypertro-
phy and mineralization during endochondral ossiﬁcation1. In
contrast to mature chondrocytes, hypertrophic cells secrete
type X collagen. Type X collagen is found in osteoarthritic
cartilage but is absent from normal adult cartilage (including
the region of the calciﬁed cartilage)24,25.
In this work, we demonstrate that OA osteoblasts induce
phenotypic changes in chondrocytes, characterized by
a decrease of SOX9, COL2 and PTHrP/PTH-R expression
and an increase of OSF-1 gene expression in chondrocytes.Materials and methods
SUBCHONDRAL OSTEOARTHRITIC OSTEOBLASTS
IN MONOLAYER CULTURE
Tibial and femoral subchondral bone plates were
obtained from the knees of cadavers (three men aged of
48, 57 and 65 years old) with OA immediately after death.
After careful elimination of trabecular bone and articular
cartilage, OA subchondral bone was dissected under
a microscope to separate N from SC zones. N and SC
zones were characterized by a marked difference in their
thickness. We have considered as SC bone only the
subchondral bone zone with a thickness greater than 2 mm
and either cartilage denuded or overlaid by ﬁbrillated
cartilage. The plates were then cut into small fragments,
washed with Dulbecco’s modiﬁed Eagle’s medium (DMEM)
and then submitted to enzymatic digestions following
a protocol from Hilal et al.6. Brieﬂy, small pieces of bone
(2 mm3) were sequentially incubated with 0.5 mg/ml hyal-
uronidase type IV S (Sigma-Aldrich, Bornem, Belgium) for
20 min at 37(C, and 0.6 mg/ml clostridial collagenase IA
(Sigma-Aldrich, Bornem, Belgium) for 30 and 240 min
successively at 37(C (2 g of bone in 20 ml of enzymatic
solution). The digested bone pieces were placed in T-75
ﬂasks and cultured in DMEM supplemented with 15% foetal
calf serum (FCS), 10 mM N-(2-hydroxyethyl) piperazin-N#-
(2-ethanesulfonic acid HEPES),100 U/ml penicillin and
100 mg/ml streptomycin, until osteoblasts migrated out of
bone explants. At this point, the medium was replaced with
fresh media containing 10% FCS, 10 mM HEPES, 100 U/ml
penicillin and 100 mg/ml streptomycin. At conﬂuence, cells
were collected by trypsinization, seeded (50,000 cells/cm2)
in 12-well plates (12-well companion plates, Falcon, BD
Biosciences, Erembodegem, Belgium) and grown for 3
days in DMEM containing 10% FCS, 100 U/ml penicillin,
100 mg/ml streptomycin, 10 mM HEPES. After washings,
osteoblasts were maintained for 12 days in a differentiation
media, composed of DMEM containing 100 U/ml penicillin,
100 mg/ml streptomycin, 10 mM HEPES, 2% Ultroser G,
a serum substitute, 108 M 1,25(OH)2vitaminD3 (Sigma-
Aldrich, Bornem, Belgium), 50 mg/ml ascorbic acid (Sigma-
Aldrich, Bornem, Belgium) and 2 mM proline (Invitrogen,
Merelbeke, Belgium). At the end of this differentiation
period, cells showed an osteoblastic phenotype character-
ized by the production of OC and ALP. Normal osteoblasts
were isolated from normal areas of subchondral bone
whereas osteoarthritic osteoblasts were isolated from the
SC areas of this tissue. After washings, cells were then
cultured for 72 h in the absence or in the presence of an
optimal dose of human recombinant IL-1b (1.7 ng/ml or
85 U/ml, Roche, Brussels, Belgium), 100 ng/ml IL-6 in
combination with 50 ng/ml IL-6 soluble receptor (IL-6sR)
(Biosource Europe, Fleurus, Belgium) or 10 ng/ml oncosta-
tin M (OSM) (Sigma-Aldrich, Bornem, Belgium). These
concentrations corresponded to the maximal IL-1b, OSM
and IL-6 concentrations found in the synovial ﬂuid of OA
patients26e28. The nutrient media used in this incubation
phase was DMEM supplemented with 1% insulin, trans-
ferrin, selenium (ITSC) (ICN Biomedicals, Asse-Relegem,
Belgium), 10 mM HEPES, 100 U/ml penicillin, 100 mg/ml
streptomycin, 50 mg/ml ascorbic acid (Sigma-Aldrich, Bor-
nem, Belgium), 2 mM proline (Invitrogen, Merelbeke,
Belgium). ITSC is a premixed cell growth system, which
contains in 1 ml: 0.625 mg insulin, 0.625 mg transferrin,
0.625 mg selenious acid, 0.125 g bovine serum albumin and
0.535 mg linoleic acid.
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Cartilage was obtained from the knees of cadavers (three
men aged 50, 52 and 63 years old) with OA immediately
after death, being excised from the superﬁcial and medium
layers of cartilage and avoiding the calciﬁed layer. Upon
dissection, the femoral, patellar and tibial articular surfaces
were evaluated for gross pathological cartilage modiﬁca-
tions according to a personal scale29. The severity of pitting
was recorded for each donor. Four different grades were
considered: 0, normal white cartilage in all areas examined;
I, the presence of a yellow-grey area with some superﬁcial
ﬁbrillations on one or more articular surfaces; II, irregular
surface with deep ﬁbrillations on one or more articular
surfaces; and III, ulcers penetrating to the subchondral
bone on one or more articular surfaces. Experiments were
performed with cartilage specimen showing OA cartilage
lesions of grade II or III. Cartilage was cut into small
fragments and then subjected to enzymatic digestions
sequentially with hyaluronidase, pronase and collagenase
(3 g of cartilage per 10 ml of enzyme solution) as previously
described30. The cells were ﬁltered through a nylon mesh
with a pore diameter of 70 mm, and then washed three times
with sterile saline. Cell viability was estimated by trypan
blue exclusion test and in all cases was superior to 95%.
Chondrocytes were suspended in 1.2% low viscosity
alginate (Sigma-Aldrich, Bornem, Belgium) in sterile saline
solution at a density of 4! 106 cells/ml, which was slowly
passed through a 25 gauge needle in a dropwise fashion
into 102 mM CaCl2 solution (Sigma-Aldrich, Bornem,
Belgium). After instantaneous gelation, the beads were
allowed to polymerize further for 10 min in this CaCl2
solution. Ten alginate beads containing OA chondrocytes
were placed in porous inserts (with 1 mm pore size; Falcon,
BD Biosciences, Erembodegem, Belgium). The chondro-
cytes in alginate beads were maintained for 2 days in
DMEM supplemented with 2% Ultroser G, 10 mM HEPES,
penicillin (100 U/ml) and streptomycin (100 mg/ml), as
a precaution to avoid contamination with drugs that donors
might have taken before death. After this wash out period,
cells were washed in phosphate buffered saline (PBS) and
the chondrocytes were placed in co-culture with osteoblasts
isolated from N or SC subchondral bone or with normal skin
ﬁbroblasts in monolayer. Normal ﬁbroblasts were obtained
by outgrowth from skin explants as previously described31.
OA OSTEOBLASTS/CHONDROCYTES CO-CULTURE
The inserts (with a pore size of 1 mm; Falcon, BD
Biosciences, Erembodegem, Belgium) containing 10 algi-
nate beads were co-cultured for 4 or 10 days with
osteoblasts in monolayer pre-incubated or not with 1.7 ng/
ml IL-1b, 100 ng/ml IL-6 or 10 ng/ml OSM. Co-culture
medium was DMEM supplemented with 1% ITSC, 10 mM
HEPES, 100 U/ml penicillin, 100 mg/ml streptomycin, 50 mg/
ml ascorbic acid, 2 mM proline. In the 10 day co-culture
experiments, the medium was changed at day 4. The co-
culture model is illustrated in Fig. 1. Six wells were pooled to
extract the RNA, and the pool was further assayed in
triplicate. The experiment was repeated three times, each
time using subchondral osteoblasts coming from a different
donor. Conversely, the origin of OA chondrocytes selected
for each experiment was from a distinct donor than
osteoblasts. As controls, OA chondrocytes in alginate
beads were cultured alone (mono-culture) or together with
normal skin ﬁbroblasts in monolayer. At the end of the
culture period, culture medium (S) were carefully collectedand kept at 20(C until analysis. The alginate beads were
dissolved in 1 ml 0.1 M citrate for 10 min. The resulting
suspension was centrifuged at 1200 rpm for 10 min. By this
method, two fractions were collected: the supernatant
containing macromolecules originated from the further-
removed matrix compartment, and a pellet, containing cells
with their associated matrix. Osteoblasts in monolayer were
collected after 5 min treatment with a solution containing
0.125% trypsin e 0.5 mM ethylenediaminetetraacetic acid
(Invitrogen, Merelbeke, Belgium). The cell pellets of
chondrocytes or osteoblasts were washed three times with
PBS and then either homogenized in 1 ml PBS by
ultrasonic dissociation for DNA and AGG quantiﬁcation or
in 175 ml of cell lysis buffer (Promega, Leiden, The Nether-
lands) for RNA isolation. Cell extracts were kept at 70(C
until analysis.
DNA ASSAY
The DNA content of the cultures was measured accord-
ing to the ﬂuorimetric method of Labarca and Paigen32.
PTHrP RADIOIMMUNOASSAY
PTHrP was assayed directly in the supernatants accord-
ing to a speciﬁc radioimmunoassay provided by Diagnostic
Systems (Oxon, UK). In this assay, the ﬁrst antibody is
coated and the second is 125I labelled. Sample incubation
with antibodies was performed overnight at ambient
temperature under constant agitation (180 rpm), rinsed with
demineralised water and counted. The detection limit of this
assay was 3 pg/ml.
QUANTITATIVE REAL-TIME REVERSE TRANSCRIPTION PCR
RNA from 3! 106 cells was isolated by spin or vacuum
total RNA isolation system (Promega, Leiden, The Nether-
lands). RNA (0.5 mg) was reverse transcribed in 30 ml buffer
containing 10 mM dithiothreitol, 1 mM deoxynucleotide
triphosphate, 500 ng (deoxythymine)15 primer, 140 U
mouse moloney leukemia virus reverse transcriptase and
40 U RNaseOUT (Life Technologies, Merelbeke, Belgium)
for 60 min at 37(C. The reaction was stopped by incubating
the samples at 95(C for 5 min, and 100 ml of H2O was
added. Polymerase chain reaction (PCR) was performed by
using the Light Cycler-FastStart DNA Master Sybr Green I
(Roche Diagnostics, Brussels, Belgium). The PCR template
source was either 3 ng ﬁrst-strand complimentary DNA
(cDNA) or puriﬁed DNA standard. Primer sequences used
to amplify the desired cDNA are detailed in Table I.
Ampliﬁcation was performed with a spectroﬂuorometric
thermal cycler (LightCycler, Roche Diagnostics, Brussels,
Belgium). After an initial denaturation step at 95(C for
10 min, ampliﬁcation was performed using 40 cycles of
denaturation (95(C for 15 s), annealing (temperature
Fig. 1. Schematic representation of the subchondral osteoblasts/
chondrocytes co-culture model.
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Primers used for real-time PCR
cDNA Sequence 5#e3# Tm pb
GAPDH Forward TTGGTATCGTGGAAGGACTCA 90.9 190
Reverse TGTCATCATATTTGGCAGGTTT
COL1A1 Forward AGTTCGAGTATGGCGG 90.7 231
Reverse CAGTGACGCTGTAGGT
COL2A1 Forward TGCTGCCCAGATGGCTGGAGGA 88.7 140
Reverse TGCCTTGAAATCCTTGAGGCCC
COL10A1 Forward GGGAGTGCCATCATCG 85 328
Reverse GAGGCTTCACATACGTTT
SOX9 Forward ACAACCCGTCTACACACAGC 85.6 369
Reverse ACGATTCTCCATCATCCTCC
OSF-1 Forward GTGACCTGAACACAGC 87 265
Reverse ACAAAGCCTACGGTACAT
PAL Forward GCTGTAAGGACATCGCC 87.1 311
Reverse GTGCTTGTATCTCGGTTT
PTHrP Forward CGGAGACTGGTTCAGC 86.5 200
Reverse GTGTGGATTTCTGCGATCA
PTH-R Forward ACCATACACCGAGGTC 85.5 183
Reverse CGTGCCTTTCGCTTGAgradient: 68e58(C with an increment of 0.5(C per cycle
during 20 cycles, continued by 20 cycles at 58(C, for 5 s)
and extension (72(C for 15 s). For each run, a standard
curve was generated from puriﬁed DNA ranging from 106 to
10 copies. To standardise messenger RNA (mRNA) levels,
we ampliﬁed GAPDH, a house keeping gene, as an internal
control. Gene expression was normalized by calculating the
ratio between the number of cDNA copies of COL1, COL2,
COL10, SOX9, OSF-1, PTHrP, PTH-R, ALP and that of
GAPDH. After ampliﬁcation, a ﬁnal melting curve was
recorded by cooling the PCR mixture to 65(C for 30 s and
then slowly heating it to 95(C at 0.1(/s. Fluorescence was
measured continuously during the slow temperature rise
to monitor the dissociation of double stranded DNA.
Speciﬁcity of the expected Lightcycler products was
demonstrated by melting curve analysis. Ampliﬁcation
products performed in the Light Cycler were checked by
electrophoresis on 1.5% ethidium bromide stained aga-
rose gel. The estimated size of the ampliﬁed fragments
matched the calculated size.
CALCULATION AND STATISTICAL ANALYSIS
The results (meanG S.E.M.) were expressed as GAPDH-
normalized gene expression. A non-parametric Manne
Whitney U test was performed on all the experiments.
Results
At the beginning of the co-culture period, 3.5G 0.5 mg of
DNA was measured in alginate beads, osteoblasts and
ﬁbroblasts monolayer culture, indicating that a similar
number of chondrocytes, osteoblasts or ﬁbroblasts were
introduced in the co-culture model. Further, co-culture
conditions did not signiﬁcantly modify DNA content in the
different compartments of the co-culture, demonstrating that
cell number remained stable over the co-culture period
(data not shown).
When they were cultured alone in alginate beads, human
OA chondrocytes spontaneously expressed after 4 days ofculture 14.25 SOX9 copies, 1.8 COL2 copies, 2.3 OSF-1
copies, 0.6 PTHrP copies and 1.98 PTH-R copies per 1000
GAPDH copies. With the exception of the PTH-R gene, the
expression of these genes was strongly decreased after 10
days of culture in alginate beads: 2.9 SOX9 copies, 0.45
COL2 copies, 0.43OSF-1 copies, 0.15PTHrP copies and2.5
PTH-R copies per 1000 GAPDH copies. The expression of
GAPDH remained stable whatever the experimental con-
ditions. In our culture conditions, ALP, COL1 and COL10
genes were not expressed by human OA chondrocytes.
INFLUENCE OF OSTEOBLASTS ON HUMAN OA
CHONDROCYTE PHENOTYPE
After 4 days in co-culture with osteoblasts isolated from N
or SC zones of OA subchondral bone, SOX9 and COL2
gene expression by human chondrocytes was signiﬁcantly
reduced [P! 0.001, Fig. 2(A)]. The inhibition of SOX9 and
COL2 gene expression was signiﬁcantly more pronounced
in the presence of SC than in the presence of N osteoblasts
(SOX9: SC 62% vs N 28%, P! 0.001; COL2: SC
78% vs N 52%, P! 0.001) [Fig. 2(A)]. When they were
co-cultured with chondrocytes, human skin ﬁbroblasts did
not modify SOX9 and COL2 gene expression.
After 10 days of co-culture, OSF-1 gene expression by
chondrocytes was increased three times (P! 0.01) in the
presence of SC osteoblasts compared to that in the
presence of N osteoblasts or mono-culture [Fig. 2(B)].
When chondrocytes in alginate beads were co-cultured
with subchondral osteoblasts for 4 days, OSF-1 mRNA
level in chondrocytes was signiﬁcantly increased. This
stimulating effect was signiﬁcantly more important when
chondrocytes were co-cultured with SC osteoblasts than
with N osteoblasts [SC C170% vs N C35%, P! 0.001,
Fig. 2(A)]. As a control, human skin ﬁbroblasts did not
modulate OSF-1 gene expression in chondrocytes.
After 10 days of co-culture, OSF-1 gene expression by
chondrocytes was three times increased (P! 0.001) in the
presence of SC osteoblasts compared to N osteoblasts or
mono-culture [Fig. 2(B)].
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or in the presence (co-culture) of osteoblasts isolated from SC or N zones of subchondral bone. As a control, human OA chondrocytes in
alginate beads were also co-cultured with normal human skin ﬁbroblasts. The results are expressed as the meanG S.E.M. of three experiments
and performed with cells coming from three different donors. The mRNA copy numbers were normalized against the corresponding copy
number of GAPDH mRNA and expressed compared to chondrocytes mono-culture. Comparison of mean values was performed by
ManneWhitney U test. Statistical signiﬁcances: chondrocytes/osteoblasts co-culture compared to mono-culture *P! 0.05 and ***P! 0.001;
SC osteoblasts compared to N osteoblasts #P! 0.05 and ###P! 0.001.After 4 days of culture, a 21-fold increase of PTHrP gene
expression in chondrocytes was observed in co-culture with
N subchondral osteoblasts [P! 0.001, Fig. 2(A)]. In
contrast, a four-fold decrease of PTHrP mRNA level in
chondrocyte occurred in co-culture with SC subchondralosteoblasts [P! 0.001, Fig. 2(A)]. In parallel, PTH-R
mRNA level in chondrocytes was enhanced by 23% in co-
culture with N osteoblasts (P! 0.05) but decreased by
37% in co-culture with SC osteoblasts [P! 0.001,
Fig. 2(A)].
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PTHrP or PTH-R gene expression by chondrocytes
[Fig. 2(B)], whereas SC osteoblasts decreased PTHrP
expression (P! 0.001).
PTHrP protein synthesis was also increased in co-culture
with N osteoblasts and decreased in co-culture with SC
osteoblasts (Fig. 3).
ALP, COL1 and COL10 genes were not expressed by OA
chondrocytes in alginate beads cultured separately or
together with osteoblasts, even after 10 days of co-culture.
EFFECT OF PRE-TREATMENT OF OSTEOBLASTS
WITH IL-1b ON HUMAN CHONDROCYTES
A 3-day pre-incubation of N or SC subchondral osteo-
blasts with IL-1b, accentuated the osteoblasts-induced
inhibition of COL2 gene expression in chondrocytes
(P! 0.01), but had no effect on SOX9 expression after 4
days of co-culture (Table II). When N, but not SC
osteoblasts, were pre-incubated with IL-1b, OSF-1 gene
expression was increased in chondrocytes (IL-1b stimulated
vs unstimulated, P! 0.01), but the level of expression did
not reach to that obtained with SC osteoblasts (Table II).
As described above, after 4 days of co-culture N
osteoblasts stimulated PTHrP gene expression and pro-
duction in chondrocytes, whereas SC osteoblasts inhibited
this gene expression. Pre-incubation of osteoblasts with IL-
1b did not modify these effects (Table II). Whilst SC
osteoblasts decreased PTH-R expression by chondrocytes,
IL-1b pre-treated SC osteoblasts had no effect (Table II).
After 10 days of co-culture, N or SC osteoblasts pre-
treated with IL-1b did not modify the behaviour of
chondrocytes (Table III), and did not induce COL1,
COL10 or ALP gene expression in chondrocytes (data not
shown).
Fig. 3. PTHrP protein measured in the culture supernatant during
the ﬁrst 4 days (0e4 days) and the following 6 days (5e10 days) of
culture. The values correspond to the cumulated production of
PTHrP by chondrocytes and osteoblasts cultured separately
(ZchondrocytesC osteoblasts mono-cultures) or the production
in co-culture. The results are expressed as the meanG S.E.M. of
three experiments assayed in triplicate and performed with cells
coming from three different donors. The results were expressed in
pg/ml. Comparison of mean values was performed by Manne
Whitney U test. Statistical signiﬁcances: chondrocytes/osteoblasts
co-culture compared to mono-culture ***P! 0.001; SC osteoblasts
compared to N osteoblasts ###P! 0.001.EFFECT OF PRE-TREATMENT OF OSTEOBLASTS WITH IL-6
OR OSM ON HUMAN CHONDROCYTES
A 3-day pre-incubation of osteoblasts with IL-6 fully
reversed the SC osteoblasts-induced inhibition of COL2
gene expression in chondrocytes after 4 days of co-culture
(P! 0.001), but had no effect on the inhibitory effect of
N osteoblasts (Table II). In contrast, the pre-incubation of
osteoblasts with OSM increased the inhibitory effect of SC
osteoblasts on COL2 gene expression by chondrocytes
(P! 0.05, Table II), but did not affect the inhibitory effect of
N osteoblasts. SOX9 gene expression by chondrocytes in
co-culture was not affected by the pre-incubation of
osteoblasts with these cytokines.
As described above, N osteoblasts stimulated PTH-R
gene expression in chondrocytes, whereas SC osteoblasts
inhibited this gene expression. When they were pre-
incubated with IL-6, N osteoblasts inhibited PTH-R gene
expression in chondrocytes (P! 0.001, Table II). In
contrast, the pre-incubation of N osteoblasts with OSM
stimulated PTH-R gene expression in chondrocytes
(P! 0.01). The inhibitory effect of SC osteoblasts on PTH-R
gene expression in chondrocytes was fully prevented by
a 3-day pre-incubation with IL-6 or OSM (Table II).
Finally, the pre-incubation of osteoblasts with IL-6 or
OSM did not modify OSF-1 gene expression or PTHrP gene
expression and production by chondrocytes in co-culture
(Tables II and III).
After 10 days of co-culture, OSM and IL-6 pre-treated
osteoblasts did not modify the responses of chondrocytes in
co-culture (Table III) and did not induce COL1, COL10 or
ALP gene expression in these cells (data not shown).
Discussion
In OA, chondrocytes undergo a phenotypic change in
gene expression pattern towards the chondroprogenitor,
hypertrophic, and dedifferentiated phenotype1,2,33,34. This
phenotypic shift is evidenced by the initiation of the
synthesis of the interstitial collagens (types I, II and
III)14,34, an increase in the synthesis of ﬁbroblast-type
proteoglycans (versican) at the expense of aggrecan35, the
re-expression of type IIA collagen33 and the expression of
a hypertrophic chondrocyte-speciﬁc molecule (type X
collagen)36,37. Although changes in the surrounding matrix,
mechanical strain and some growth factors and cytokines
have been demonstrated to alter the pattern of genes
expression in chondrocyte, the circumstances leading to
long-term changes in the phenotype of the cell remain
poorly understood. Herein, we assume that factors pro-
duced by OA osteoblasts could induce phenotype shift in
OA chondrocytes. OA has been associated with a thicken-
ing of subchondral bone, and also with abnormally low
mineralization pattern. In this respect, it is also important to
note that Shimizu et al.38 have shown, using a large number
of patients, that progression of joint cartilage degeneration
is associated with intensiﬁed remodelling of subchondral
bone and increased bone stiffness. This is strongly
indicative of a cellular bone defect in OA. The hypothesis
that abnormal OA osteoblasts directly inﬂuence cartilage
metabolism was previously put forward by Westacott et al.3.
These authors have shown that conditioned media from
primary osteoblasts of OA patients vs subject without
arthritis signiﬁcantly enhanced glycosaminoglycans release
from normal cartilage. Furthermore, Hilal et al.6,7 have
reported that in vitro primary culture of osteoblasts prepared
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Gene expression by chondrocytes after 4 days of co-culture with osteoblasts isolated from N or SC OA subchondral bone plate. Before co-
culture, human osteoblasts were either pre-incubated or not (control) for 72 h with IL-1b (1.7 ng/ml), IL-6 (100 ng/ml in combination with 50 ng/
ml of IL-6sR), or OSM (10 ng/ml). Results are expressed as the percentage of the chondrocyte mono-culture (alginate beads only), or as the
percentage of the cumulated production of PTHrP protein by chondrocytes and osteoblasts cultivated separately (mono-cultures), and
represented by the meanG S.E.M. of three independent experiments, each assayed in triplicate. Statistical significance: between co-culture
and mono-culture *P! 0.05, **P! 0.01 and ***P! 0.001, between N and SC osteoblasts #P! 0.05, ##P! 0.01 and ###P! 0.001,
between basal and cytokine pre-incubated osteoblasts ˆP! 0.05, ˆ ˆP! 0.01 and ˆ ˆ ˆP! 0.001
4 days of osteoblasts/chondrocytes co-culture
Basal IL-1b IL-6/IL-6sR OSM
GAPDH N 101G 4.2 98G 7.2 106G 7.1 99G 5.1
SC 96G 6.2 102G 6.3 97G 6.5 96G 7.8
COL2 N 48.5G 3.4*** 38.7G 2.7*** 51.1G 3.5*** 62.9G 4.4***
SC 19.9G 1.4###,*** 16.6G 1.2###,*** 105.1G 7.2###,ˆ ˆ ˆ 14.2G 1.0###,***, ˆ
SOX9 N 70.9G 4.9*** 66.7G 4.6*** 58.9G 4.1*** 66.7G 4.7***
SC 37.9G 2.6###,*** 43.2G 3.1###,*** 36.4G 2.5###,*** 39.4G 2.8###,***
OSF-1 N 134.8G 9.1* 195.6G 13.7***, ˆ ˆ 126.1G 8.8 130.4G 9.1
SC 269.5G 18.7###,*** 282.6G 19.6###,*** 304.3G 21.3###,*** 347.8G 24.3###,***
PTHrP mRNA N 1683G 116*** 1583G 110*** 1402G 98*** 1583G 111***
SC 23.2G 1.5###,*** 40.5G 2.8###,*** 38.8G 2.7###,*** 24.9G 1.7###,***
PTHrP protein N 246.0G 34.5*** 253.0G 41.2*** 261.4G 53.1*** 234.5G 43.8***
SC 60.2G 7.9###,*** 67.2G 8.9###,*** 64.5G 9.4###,*** 68.1G 11.2###,***
PTH-R N 122.5G 10.1* 121.4G 6.2* 75.8G 3.8**, ˆ ˆ ˆ 138.2G 12.0**
SC 63.1G 3.2###,*** 102.3G 5.1#, ˆ ˆ ˆ 100.2G 5.0##, ˆ ˆ ˆ 126.0G 6.3*, ˆ ˆ ˆfrom human OA subchondral bone plates showed an
altered phenotype, and that uPA/plasmin system activity
and IGF-1 levels are altered in these cells. In a previous
work, we have shown that SC osteoblasts overproduced
cytokines and growth factor, such as IL-6 and TGF-b1 (see
Ref.9), that are involved in local remodelling of bone tissues,
and these could also contribute to remodelling the overlying
cartilage after seeping through microcracks in the calciﬁed
layer of articular cartilage. Whether these changes in
subchondral bone cells are responsible for OA or contributeto its progression is not deﬁnitely known. To better explore
this pathophysiological axis, we have developed a co-
culture system in which osteoblasts isolated from the SC
area of the OA subchondral bone are cultured simulta-
neously with OA chondrocytes. In a previous work, we have
clearly demonstrated that osteoblasts isolated from the SC
OA subchondral bone induced a signiﬁcant inhibition of
aggrecan production and a signiﬁcant increase of MMP-3
and MMP-13 synthesis9. These metabolic changes are
related to the SC phenotype of osteoblasts as suggested byTable III
Gene expression by chondrocytes after 10 days of co-culture with osteoblasts isolated from N or SC OA subchondral bone plate. Before co-
culture, human osteoblasts were either pre-incubated or not (control) for 72 h with IL-1b (1.7 ng/ml), IL-6 (100 ng/ml in combination with 50 ng/
ml of IL-6sR), or OSM (10 ng/ml). Results are expressed as the percentage of the chondrocyte mono-culture (alginate beads only) or as the
percentage of the cumulated production of PTHrP protein by chondrocytes and osteoblasts cultivated separately (mono-cultures), and
represented by the meanG S.E.M. of three independent experiments, each assayed in triplicate. Statistical significance: between co-culture
and mono-culture ***P! 0.001, between N and SC osteoblasts #P! 0.05, ##P! 0.01 and ###P! 0.001
10 days of osteoblasts/chondrocytes co-culture
Basal IL-1b IL-6/IL-6sR OSM
GAPDH N 105G 6.5 96G 7.6 103G 5.3 94G 8.4
SC 101G 3.3 105G 4.4 96G 5.4 98G 5.3
COL2 N 84.4G 13.1 91.1G 10.9 93.3G 14.4 80.1G 8.8
SC 57.8G 5.6#,*** 66.7G 4.7##,*** 64.4G 7.3#,*** 56.9G 3.9##,***
SOX9 N 96.5G 16 93.1G 15.8 95.5G 12.3 86.3G 12.6
SC 102.7G 13 88.6G 14.8 95.2G 12.5 104.8G 13.5
OSF-1 N 106G 19 116.3G 16.6 120.2G 18.4 118.6G 19.2
SC 309.7G 21.9###,*** 249.8G 29.8###,*** 260.5G 22.1###,*** 279.1G 19.9###,***
PTHrP mRNA N 82.9G 21.3 116.4G 25.1 96.6G 17.7 84.9G 25.1
SC 27.4G 6.6###,*** 34.2G 11.6###,*** 39.7G 10.9###,*** 37.6G 9.6###,***
PTHrP protein N 102.0G 15.8 104.4G 5.9 94.6G 10.3 89.8G 12.4
SC 79.0G 13.8 85.4G 11.1 91.2G 18.7 87.7G 8.6
PTH-R N 120.2G 16.2 110.8G 12.8 120.4G 10.8 135.5G 21.5
SC 89.6G 10.4 95.2G 4.0 119.3G 11.9 104.0G 16.9
995Osteoarthritis and Cartilage Vol. 13, No. 11the absence of effect of osteoblasts isolated from N
subchondral bone and skin ﬁbroblasts. In our culture
condition, SC osteoblasts secrete more ALP, OC, IL-6
and TGF-b1 than N cells corroborating the results of some
previous work comparing normal and OA osteoblasts5,6.
These ﬁndings indicate that SC subchondral osteoblasts
used in this study showed an altered phenotype compared
to osteoblasts isolated from N subchondral bone, and that
within the subchondral bone, local changes in osteoblasts
can occur. These local metabolic changes in subchondral
bone could result from abnormal mechanical stress39. We
also hypothesized that OA chondrocytes contribute or
modulate these changes in osteoblasts through the
localized microfractures. Nevertheless, this pathological
pathway needs to be demonstrated. In this work, we have
demonstrated that osteoblasts, essentially SC osteoblasts,
decreased COL2, SOX9 and PTHrP/PTH-R gene expres-
sion but increased OSF-1 mRNA level. For the ﬁrst time,
these data indicate that SC osteoblasts may induce
alteration in the gene expression pattern of OA chondro-
cytes and initiate phenotypic changes in these cells.
Indeed, OSF-1, which is not expressed by normal chon-
drocytes (personal communication), is expressed by OA
chondrocytes. These data corroborate those of Pufe et al.21
demonstrating that OSF-1 is re-expressed in OA cartilage.
In our co-culture model, OSF-1 mRNA level is highly
(C170%) increased by SC, but very slightly by N
osteoblasts (C35%), indicating that this effect is related to
the SC phenotype of OA subchondral osteoblasts. Our
study proposes a new regulatory pathway involving
osteoblasts stimulation of OSF-1 expression in OA carti-
lage. In parallel, SC osteoblasts downregulate SOX9
expression. During endochondral ossiﬁcation, the expres-
sion of SOX9 gene and of COL2A1 is high in resting and
proliferating cells, and rapidly turned off when chondrocytes
undergo hypertrophy in the end of their differentiation
pathway40. These ﬁndings indicate that SOX9 expression
is essential to maintain the chondrocyte-speciﬁc phenotype.
Interestingly, SOX9 mRNA level was decreased in OA
cartilage41, suggesting that SOX9 expression decrease
could be a marker of the onset of chondrocyte phenotype
shift in OA. One of the most interesting results of our study
is that SC osteoblasts decrease PTHrP and PTH-R
expression in OA chondrocytes, whereas osteoblasts
isolated from N subchondral bone increase both PTHrP
and PTH-R expression. In endochondral ossiﬁcation,
PTHrP participates in a negative feedback loop regulating
the onset of hypertrophic differentiation42. Again, our data
suggest that SC osteoblasts could contribute to hypertro-
phic differentiation of chondrocyte by suppressing the
inhibitory retrocontrol exerted by PTHrP. Thus, a decrease
of SOX9 and PTHrP/PTH-R and an increase of OSF-1 gene
expression could be interpreted as a signal of chondrocyte
phenotype shift towards hypertrophic phenotype. Neverthe-
less, we fail to demonstrate the expression by chondrocyte
of type X, which is considered as a molecule speciﬁcally
expressed by hypertrophic cells. Our study has some
limitations. The most important is the duration of the
observation that is limited to the ﬁrst 10 days of culture.
We cannot exclude that this culture period is too short to
allow a complete differentiation process. Indeed, other
authors have demonstrated that in vitro type X collagen is
expressed by chondrocytes after 11 days in a 5-azacytidine
treated monolayer model43. Further research works are
needed to investigate the long-term effect of OA osteoblasts
on the hypertrophic differentiation of OA chondrocytes.
Moreover, we cannot exclude that chondrocyte phenotypicalchanges were limited by our culture conditions. In alginate
beads, cartilage matrix is formed during the ﬁrst 6 days and
thereafter remains in homeostasis30,44. Further, we have
observed that some genes involved in chondrogenesis
were highly expressed after the ﬁrst 4 days of culture, but
expressed in very low level after 10 days, indicating
a stabilization of the chondrocyte phenotype. This obser-
vation is in agreement with those of Binette et al.45 who
have reported that type X collagen and osteopontin were
not expressed by articular chondrocytes cultivated in
alginate beads, even after 5 months.
We have also co-cultured human OA chondrocytes with
N or SC osteoblasts pre-incubated with IL-1b, IL-6 or OSM.
We have tested these cytokines because they play an
important role in bone remodelling and they could be
involved in bone sclerosis process that occurs in OA. IL-6,
in the presence of IL-6sR, increases collagenase-3 and
IGF-1 expression in osteoblasts from foetal rat calvar-
iae46,47. IL-6 also stimulates bone resorption by increasing
osteoclasts recruitment and differentiation. The effects of
IL-6 on osteoclasts recruitment require the presence of
osteoblasts and depend on IL-6 receptors and receptor
activator of nuclear factor kB (RANK)/RANK ligand
(RANKL)48. In primary neonatal murine or foetal rat
calvariae osteoblasts culture, OSM induces proliferation,
collagen synthesis, and IL-6 secretion, whereas it inhibits
ALP49. In primary culture of rat osteoblast cells, IL-1b
decreases OC synthesis but has no effect on ALP activity50.
IL-1b also stimulates PTHrP, PGE2, IL-6 and uPA secretion
and decreases TGF-b1 production by human osteoblast-
like cells51e53. In a previous study, we have demonstrated
that IL-1b, IL-6 and OSM increased ALP, but decreased
OC synthesis by normal osteoblasts. Further, IL-6 and OSM
increased TGF-b synthesis but had no effect on IL-1b
production by normal osteoblasts9. Curiously, IL-1b, IL-6,
or OSM pre-incubated N osteoblasts did not modify SOX9,
COL2, or PTHrP/PTH-R mRNA levels in OA chondrocytes.
These data suggest that IL-1b, IL-6 or OSM-treated N
osteoblasts fail to reproduce SC osteoblasts-induced
phenotype shift in chondrocytes, and that probably TGF-
b1, which is increased by IL-6 and OSM, is not the
mediator of the OA-osteoblasts effects. We are aware that
further investigations are needed to identify the factor(s)
involved in the SC osteoblasts effects. Some potential
candidate could be responsible for these effects. For
example, IL-1b is known to decrease COL2 and SOX9
expression by chondrocytes54. However, we have pre-
viously shown that N and SC osteoblasts produced similar
amount of IL-1b (see Ref.9), so it’s probably not this factor
that is involved in the present results. IL-6 is overproduced
and therefore could be the mediators of osteoblasts
effects. In fact, IL-6/IL-6sR has been shown to decrease
COL2 and SOX9 gene expression by chondrocytes55. To
verify these hypotheses, we have programmed some
experiments using neutralizing antibodies against numer-
ous cytokines and growth factors. The results will be
published in a separate paper.
In summary, our work demonstrates that SC osteoblasts
induced a phenotypic shift in OA chondrocytes that could
lead to hypertrophic phenotype and subsequently to matrix
mineralization. Interestingly, IL-1b, IL-6 or OSM-treated
osteoblasts isolated from N subchondral bone fail to
reproduce the SC osteoblasts effects, suggesting that the
factor(s) involved in this process is (are) not produced or
produced in an inactive form by IL-1b, IL-6 or OSM
stimulated normal osteoblasts. These ﬁndings provide
further insights into the pathogenic role of osteoblasts in OA.
996 C. Sanchez et al.: Osteoblasts-induced phenotype shift in chondrocyteAcknowledgements
The authors would like to thank Alain Labasse, Philippe
Devel, Paul Simonis and Murielle Lemestre for their skilful
technical assistance. This work was supported by a grant
from Laboratoire Expanscience, France. Christelle Sanchez
was supported as a pre-doctoral fellow by Belgian F.N.R.S.
References
1. Pfander D, Swoboda B, Kirsch T. Expression of early
and late differentiation markers (proliferating cell
nuclear antigen, syndecan-3, annexin VI, and alkaline
phosphatase) by human osteoarthritic chondrocytes.
Am J Pathol 2001;159:1777e83.
2. Pullig O, Weseloh G, Ronneberger D, Kakonen S,
Swoboda B. Chondrocyte differentiation in human
osteoarthritis: expression of osteocalcin in normal and
osteoarthritic cartilage and bone. Calcif Tissue Int
2000;67:230e40.
3. Westacott CI, Webb GR, Warnock MG, Sims JV, Elson
CJ. Alteration of cartilage metabolism by cells from
osteoarthritic bone. Arthritis Rheum 1997;40:
1282e91.
4. Guevremont M, Martel-Pelletier J, Massicotte F,
Tardif G, Pelletier JP, Ranger P, et al. Human
adult chondrocytes express hepatocyte growth factor
(HGF) isoforms but not HgF: potential implication
of osteoblasts on the presence of HGF in cartilage.
J Bone Miner Res 2003;18:1073e81.
5. Massicotte F, Lajeunesse D, Benderdour M, Pelletier
JP, Hilal G, Duval N, et al. Can altered production of
interleukin-1beta, interleukin-6, transforming growth
factor-beta and prostaglandin E(2) by isolated human
subchondral osteoblasts identify two subgroups of
osteoarthritic patients. Osteoarthritis Cartilage 2002;
10:491e500.
6. Hilal G, Martel-Pelletier J, Pelletier JP, Ranger P,
Lajeunesse D. Osteoblast-like cells from human
subchondral osteoarthritic bone demonstrate an al-
tered phenotype in vitro: possible role in subchondral
bone sclerosis. Arthritis Rheum 1998;41:891e9.
7. Hilal G, Martel-Pelletier J, Pelletier JP, Duval N,
Lajeunesse D. Abnormal regulation of urokinase
plasminogen activator by insulin-like growth factor 1
in human osteoarthritic subchondral osteoblasts.
Arthritis Rheum 1999;42:2112e22.
8. Hilal G, Massicotte F, Martel-Pelletier J, Fernandes JC,
Pelletier JP, Lajeunesse D. Endogenous prostaglan-
din E2 and insulin-like growth factor 1 can modulate
the levels of parathyroid hormone receptor in human
osteoarthritic osteoblasts. J Bone Miner Res 2001;16:
713e21.
9. Sanchez C, Deberg MA, Piccardi N, Msika P, Reginster
JY, Henrotin Y. Osteoblasts from the sclerotic sub-
chondral bone downregulate aggrecan but upregulate
metalloproteinases expression by chondrocytes. This
effect is mimicked by interleukin-6, -1b and oncostatin
M pre-treated non sclerotic osteoblasts. Osteoarthritis
Cartilage, in press.
10. Bi W, Deng JM, Zhang Z, Behringer RR, de Crom-
brugghe B. Sox9 is required for cartilage formation.
Nat Genet 1999;22:85e9.
11. Ng LJ, Wheatley S, Muscat GE, Conway-Campbell J,
Bowles J, Wright E, et al. SOX9 binds DNA, activatestranscription, and coexpresses with type II collagen
during chondrogenesis in the mouse. Dev Biol 1997;
183:108e21.
12. ZhaoQ,EberspaecherH, LefebvreV, deCrombruggheB.
Parallel expression of Sox9 and Col2a1 in cells
undergoing chondrogenesis. Dev Dyn 1997;209:
377e86.
13. Goldwasser M, Astley T, van der Rest M, Glorieux FH.
Analysis of the type of collagen present in osteoar-
thritic human cartilage. Clin Orthop 1982;296e302.
14. Aigner T, Gluckert K, von der Mark K. Activation of
ﬁbrillar collagen synthesis and phenotypic modulation
of chondrocytes in early human osteoarthritic cartilage
lesions. Osteoarthritis Cartilage 1997;5:183e9.
15. Stokes DG, Liu G, Coimbra IB, Piera-Velazquez S,
Crowl RM, Jimenez SA. Assessment of the gene
expression proﬁle of differentiated and dedifferentiated
human fetal chondrocytes by microarray analysis.
Arthritis Rheum 2002;46:404e19.
16. Lee K, Lanske B, Karaplis AC, Deeds JD, Kohno H,
Nissenson RA, et al. Parathyroid hormone-related
peptide delays terminal differentiation of chondrocytes
during endochondral bone development. Endocrinology
1996;137:5109e18.
17. Iwamoto M, Jikko A, Murakami H, Shimazu A,
Nakashima K, Takigawa M, et al. Changes in para-
thyroid hormone receptors during chondrocyte cyto-
differentiation. J Biol Chem 1994;269:17245e51.
18. Amling M, Neff L, Tanaka S, Inoue D, Kuida K, Weir E,
et al. Bcl-2 lies downstream of parathyroid hormone-
related peptide in a signaling pathway that regulates
chondrocyte maturation during skeletal development.
J Cell Biol 1997;136:205e13.
19. Vortkamp A, Lee K, Lanske B, Segre GV, Kronenberg
HM, Tabin CJ. Regulation of rate of cartilage
differentiation by Indian hedgehog and PTH-related
protein. Science 1996;273:613e22.
20. Okano K, Tsukazaki T, Ohtsuru A, Osaki M,
Yonekura A, Iwasaki K, et al. Expression of para-
thyroid hormone-related peptide in human osteo-
arthritis. J Orthop Res 1997;15:175e80.
21. Pufe T, BartscherM, PetersenW, TillmannB, Mentlein R.
Pleiotrophin, an embryonic differentiation and growth
factor, is expressed in osteoarthritis. Osteoarthritis
Cartilage 2003;11:260e4.
22. Yang X, Tare RS, Partridge KA, Roach HI, Clarke NM,
Howdle SM, et al. Induction of human osteoprogenitor
chemotaxis, proliferation, differentiation, and bone
formation by osteoblast stimulating factor-1/pleiotro-
phin: osteoconductive biomimetic scaffolds for tissue
engineering. J Bone Miner Res 2003;18:47e57.
23. Tapp H, Hernandez DJ, Neame PJ, Koob TJ. Pleio-
trophin inhibits chondrocyte proliferation and stimu-
lates proteoglycan synthesis in mature bovine
cartilage. Matrix Biol 1999;18:543e56.
24. Girkontaite I, Frischholz S, Lammi P, Wagner K,
Swoboda B, Aigner T, et al. Immunolocalization of
type X collagen in normal fetal and adult osteoarthritic
cartilage with monoclonal antibodies. Matrix Biol 1996;
15:231e8.
25. Boos N, Nerlich AG, Wiest I, von der Mark K, Ganz R,
Aebi M. Immunohistochemical analysis of type-X-
collagen expression in osteoarthritis of the hip joint.
J Orthop Res 1999;17:495e502.
26. Okamoto H, Yamamura M, Morita Y, Harada S,
Makino H, Ota Z. The synovial expression and serum
levels of interleukin-6, interleukin-11, leukemia inhibitory
997Osteoarthritis and Cartilage Vol. 13, No. 11factor, and oncostatin M in rheumatoid arthritis. Arthritis
Rheum 1997;40:1096e105.
27. Saxne T, Di Giovine FS, Heinegard D, Duff GW,
Wollheim FA. Synovial ﬂuid concentrations of in-
terleukin-1 beta and proteoglycans are inversely
related. J Autoimmun 1988;1:373e80.
28. Uson J, Balsa A, Pascual-Salcedo D, Cabezas JA,
Gonzalez-Tarrio JM, Martin-Mola E, et al. Soluble
interleukin 6 (IL-6) receptor and IL-6 levels in serum
and synovial ﬂuid of patients with different arthropa-
thies. J Rheumatol 1997;24:2069e75.
29. Henrotin Y, Labasse A, Zheng SX, Galais P,
Tsouderos Y, Crielaard JM, et al. Strontium ranelate
increases cartilage matrix formation. J Bone Miner Res
2001;16:299e308.
30. Sanchez C, Mateus MM, Defresne MP, Crielaard JM,
Reginster JY, Henrotin YE. Metabolism of human
articular chondrocytes cultured in alginate beads.
Longterm effects of interleukin 1beta and nonsteroidal
antiinﬂammatory drugs. J Rheumatol 2002;29:
772e82.
31. Delvoye P, Wiliquet P, Leveque JL, Nusgens BV,
Lapiere CM. Measurement of mechanical forces
generated by skin ﬁbroblasts embedded in a three-
dimensional collagen gel. J Invest Dermatol 1991;97:
898e902.
32. Labarca C, Paigen K. A simple, rapid, and sensitive
DNA assay procedure. Anal Biochem 1980;102:
344e52.
33. Aigner T, Zhu Y, Chansky HH, Matsen FA 3rd, Maloney
WJ, Sandell LJ. Reexpression of type IIA procollagen
by adult articular chondrocytes in osteoarthritic carti-
lage. Arthritis Rheum 1999;42:1443e50.
34. Gebhard PM, Gehrsitz A, Bau B, Soder S, Eger W,
Aigner T. Quantiﬁcation of expression levels of cellular
differentiation markers does not support a general shift
in the cellular phenotype of osteoarthritic chondro-
cytes. J Orthop Res 2003;21:96e101.
35. Nishida Y, Shinomura T, Iwata H, Miura T, Kimata K.
Abnormal occurrence of a large chondroitin sulfate
proteoglycan, PG-M/versican in osteoarthritic carti-
lage. Osteoarthritis Cartilage 1994;2:43e9.
36. Walker GD, Fischer M, Gannon J, Thompson RC Jr,
Oegema TR Jr. Expression of type-X collagen in
osteoarthritis. J Orthop Res 1995;13:4e12.
37. von der Mark K, Frischholz S, Aigner T, Beier F, Belke J,
Erdmann S, et al. Upregulation of type X collagen
expression in osteoarthritic cartilage. Acta Orthop
Scand Suppl 1995;266:125e9.
38. Shimizu M, Tsuji H, Matsui H, Katoh Y, Sano A.
Morphometric analysis of subchondral bone of the
tibial condyle in osteoarthrosis. Clin Orthop 1993;
229e39.
39. Kaspar D, Seidl W, Neidlinger-Wilke C, Claes L. In vitro
effects of dynamic strain on the proliferative and
metabolic activity of human osteoblasts. J Musculos-
kelet Neuronal Interact 2000;1:161e4.
40. Lefebvre V, Behringer RR, de Crombrugghe B. L-Sox5,
Sox6 and Sox9 control essential steps of the
chondrocyte differentiation pathway. Osteoarthritis
Cartilage 2001;9(Suppl A):S69e75.
41. Aigner T, Gebhard PM, Schmid E, Bau B, Harley V,
Poschl E. SOX9 expression does not correlate with
type II collagen expression in adult articular chondro-
cytes. Matrix Biol 2003;22:363e72.42. Suda N, Shibata S, Yamazaki K, Kuroda T, Senior PV,
Beck F, et al. Parathyroid hormone-related protein
regulates proliferation of condylar hypertrophic chon-
drocytes. J Bone Miner Res 1999;14:1838e47.
43. Cheung JO, Hillarby MC, Ayad S, Hoyland JA, Jones
CJ, Denton J, et al. A novel cell culture model of
chondrocyte differentiation during mammalian endo-
chondral ossiﬁcation. J Bone Miner Res 2001;16:
309e18.
44. Sanchez C, Deberg MA, Burton S, Devel P, Reginster
JY, Henrotin Y. Differential regulation of chondrocyte
metabolism by oncostatin M and interleukin-6. Oste-
oarthritis Cartilage 2004;10:801e10.
45. Binette F, McQuaid DP, Haudenschild DR, Yaeger PC,
McPherson JM, Tubo R. Expression of a stable
articular cartilage phenotype without evidence of
hypertrophy by adult human articular chondrocytes
in vitro. J Orthop Res 1998;16:207e16.
46. Franchimont N, Rydziel S, Delany AM, Canalis E.
Interleukin-6 and its soluble receptor cause a marked
induction of collagenase 3 expression in rat osteoblast
cultures. J Biol Chem 1997;272:12144e50.
47. Franchimont N, Gangji V, Durant D, Canalis E.
Interleukin-6 with its soluble receptor enhances the
expression of insulin-like growth factor-I in osteo-
blasts. Endocrinology 1997;138:5248e55.
48. Palmqvist P, Persson E, Conaway HH, Lerner UH. IL-6,
leukemia inhibitory factor, and oncostatin M stimulate
bone resorption and regulate the expression of
receptor activator of NF-kappa B ligand, osteoprote-
gerin, and receptor activator of NF-kappa B in mouse
calvariae. J Immunol 2002;169:3353e62.
49. Jay PR, Centrella M, Lorenzo J, Bruce AG, Horowitz
MC. Oncostatin-M: a new bone active cytokine that
activates osteoblasts and inhibits bone resorption.
Endocrinology 1996;137:1151e8.
50. Taichman RS, Hauschka PV. Effects of interleukin-1
beta and tumor necrosis factor-alpha on osteoblastic
expression of osteocalcin and mineralized extracellu-
lar matrix in vitro. Inﬂammation 1992;16:587e601.
51. Evans DB, Thavarajah M, Kanis JA. Involvement of
prostaglandin E2 in the inhibition of osteocalcin
synthesis by human osteoblast-like cells in response
to cytokines and systemic hormones. Biochem Bio-
phys Res Commun 1990;167:194e202.
52. Tsai JA, Rong H, Torring O, Matsushita H, Bucht E.
Interleukin-1beta upregulates PTHrP-mRNA expres-
sion and protein production and decreases TGF-beta
in normal human osteoblast-like cells. Calcif Tissue Int
2000;66:363e9.
53. Takaoka Y, Niwa S, Nagai H. Interleukin-1beta induces
interleukin-6 production through the production of
prostaglandin E(2) in human osteoblasts, MG-63 cells.
J Biochem (Tokyo) 1999;126:553e8.
54. Majumdar MK, Wang E, Morris EA. BMP-2 and BMP-9
promotes chondrogenic differentiation of human multi-
potential mesenchymal cells and overcomes the in-
hibitory effect of IL-1. J Cell Physiol 2001;189:275e84.
55. Legendre F, Dudhia J, Pujol JP, Bogdanowicz P.
JAK/STAT but not ERK1/ERK2 pathway mediates
interleukin (IL)-6/soluble IL-6R down-regulation of
Type II collagen, aggrecan core, and link protein
transcription in articular chondrocytes. Association
with a down-regulation of SOX9 expression. J Biol
Chem 2003;278:2903e12.
